FUB-NPB-22 |
Catalog No.GC43705 |
PB-22, first reported in 2013, introduced 8-hydroxyquinoline as a substitution for the naphthalene group on traditional JWH-type synthetic cannabinoids.
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
PB-22 , first reported in 2013, introduced 8-hydroxyquinoline as a substitution for the naphthalene group on traditional JWH-type synthetic cannabinoids. [1][2] The analog NPB-22 differs from PB-22 by the replacement of indazole for indole. FUB-NPB-22 is an analog of NPB-22 in which the pentyl side chain is replaced by a 4-fluorobenzyl group. The physiological and toxicological properties of this compound are not known. This product is intended for forensic and research applications.
Reference:
[1]. Uchiyama, N., Matsuda, S., Kawamura, M., et al. Identification of two new-type designer drugs, piperazine derivative MT-45 (I-C6) and synthetic peptide Noopept (GVS-111), with synthetic cannabinoid A-834735, cathinone derivative 4-methoxy-α-PVP, and phenethylamine derivative 4-methylbuphedrine from illegal products. Forensic Toxicol. (2013).
[2]. Uchiyama, N., Matsuda, S., Kawamura, M., et al. Two new-type cannabimimetic quinolinyl carboxylates, QUPIC and QUCHIC, two new cannabimimetic carboxamide derivatives, ADB-FUBINACA and ADBICA, and five synthetic cannabinoids detected with a thiophene derivative α-PVT and an opioid receptor agonist AH-7921 identified in illegal products. Forensic Toxicol. 31(2), 223-240 (2013).
Average Rating: 5
(Based on Reviews and 10 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *